Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 29, 2025, titled "Zydus receives EIR for the Baddi manufacturing facility".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Baddi, Himachal Pradesh. An EIR is the formal document the FDA issues after completing and closing out an inspection of a drug manufacturing site. Receiving an EIR generally means the FDA has concluded its review of the facility and classified its compliance status. The Baddi plant is part of Zydus's network that produces medicines, including formulations and APIs, for both domestic and export markets. The press release dated October 29, 2025 confirms the conclusion of this regulatory milestone without any further public detail on the specific classification (such as No Action Indicated or Voluntary Action Indicated).
This is a positive regulatory update for shareholders, as closure of the FDA inspection at Baddi supports uninterrupted manufacturing and supply of products from this facility, particularly for the important US market, removing any near-term compliance overhang on the stock.